EU Delays Approval of Novavax's Revised Covid Jab and Nears Deal with UK to Delay Post-Brexit EV Tariffs
The European Union has delayed the approval of Novavax's revised Covid-19 vaccine, prolonging the wait for the shot to be authorized for use in the region. The EU's drug regulator, the European Medicines Agency (EMA), stated that it needs more data on the vaccine's efficacy and safety before making a decision. Novavax had submitted additional data to address concerns raised during the initial review process. The delay in approval adds to the challenges faced by the EU in its vaccination campaign.